Physician profile
Otto L Secada
NPI 1942297205
$3,927.33
in general payments reported to CMS, 2019-2025
25 companies · $623 in 2025
The $623 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $743 · 2020: $703 · 2021: $433 · 2022: $619 · 2023: $438 · 2024: $368 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,429.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $721.56 | 2019-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $710.23 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $473.02 | 2019-2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $311.58 | 2019-2024 | Jardiance |
| Amarin Pharma, INC. | $254.84 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $207.83 | 2019-2024 | Xifaxan, Trulance |
| Abbott Laboratories | $181.89 | 2022-2025 | Freestyle Libre |
| Glaxosmithkline, LLC. | $180.04 | 2021-2024 | Arexvy, Trelegy Ellipta |
| Amgen INC. | $129.99 | 2023-2025 | Repatha, Otezla, Repatha |
| Angiodynamics, INC. | $123.57 | 2022 | |
| Sanofi-Aventis U.S. LLC | $112.72 | 2019-2020 | |
| Abbvie INC. | $86.15 | 2021-2023 | Vraylar |
| Sumitomo Pharma America, INC. | $69.10 | 2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $63.21 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $58.58 | 2021-2025 | Zoryve |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $39.38 | 2019-2021 | |
| Pfizer INC. | $37.01 | 2019-2021 | |
| Allergan, INC. | $35.61 | 2019-2020 | |
| Exact Sciences Corporation | $23.02 | 2025 | The Cologuard Plus Collection Kit |
| Metuchen Pharmaceuticals | $21.59 | 2019 | |
| Janssen Pharmaceuticals, INC | $20.35 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.00 | 2022 | |
| Ibsa Pharma INC. | $16.67 | 2023 | Tirosint, Licart |
| Hikma Pharmaceuticals USA | $16.67 | 2023 | Ryaltris, Mitigare |
| Astellas Pharma US INC | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Otto Secada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.